quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 2, 2026

Trending tickers: Palantir, Berkshire Hathaway, Lockheed Martin, Exxon Mobil and Bunzl

View original at uk.finance.yahoo.com
Trending tickers: Palantir, Berkshire Hathaway, Lockheed Martin, Exxon Mobil and Bunzl Palantir (PLTR) Shares of Palantir were the top-trending ticker on Yahoo Finance on Monday morning after UBS (UBS) upgraded the company…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Palantir is facing a very strong demand backdrop as it sits at the intersection of AI and data spend. This investment ramp in AI models and data is occurring right now, with Palantir a clear AI winner

    80% confidence
  • Greg Abel will continue the culture Buffett built of financial strength and capital discipline

    80% confidence
  • The most immediate and tangible development affecting oil markets is the effective halt of traffic through the Strait of Hormuz, preventing 15 million barrels per day of crude oil from reaching markets. Unless de-escalation signals emerge swiftly, we expect a significant upward repricing of oil.

    80% confidence
  • The market will take this as broadly positive for European defense stocks, though any move is likely to be driven more by sentiment than by changes to earnings estimates

    80% confidence
  • The push for additional military funding may now spread to the Middle East, with US contractors capturing much of that new business from the region which already accounts for a significant portion of their foreign military sales

    80% confidence
  • Investors should consider taking advantage of this -35% move off the peak for the premier growth story in software

    80% confidence
  • Higher oil and gas prices are almost certain, with prices possibly exceeding $100 per barrel if tanker flows through the Strait of Hormuz are not quickly restored

    80% confidence
  • After a couple of bruising years for the share price, Bunzl investors were handed a steadier, if hardly sparkling, set of results. Management's interventions in North America including leadership changes and cost controls appear to be paying off.

    80% confidence
  • For the most part, Bunzl remains a well-run if not currently well-regarded stock. The outlook provides little for the bulls to feed on. The market consensus of hold reflects investors' reticence to become involved until a sustained recovery is in evidence.

    80% confidence
  • Palantir stock is very attractive at 50 times UBS's 2027 free cash flow estimates given 70% revenue growth in 2026 and mid-50% operating margins

    80% confidence
  • In the current scenario, oil prices over US$100/bbl are possible if transit flows are not re-established quickly. The key question is when do vessels re-establish export flows.

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Trending tickers: Palantir, Berkshire Hathaway, Lockheed Martin, Exxon Mobil and Bunzl — Source | Via News | pt.VIA.NEWS